{"id":751,"date":"2026-04-13T05:16:30","date_gmt":"2026-04-13T05:16:30","guid":{"rendered":"https:\/\/luciuspharmacy.com\/?post_type=product&p=751"},"modified":"2026-08-30T03:53:26","modified_gmt":"2026-08-30T03:53:26","slug":"luciveric-vericiguat-10-mgx98-tablets","status":"publish","type":"product","link":"https:\/\/luciuspharmacy.com\/pt\/product\/luciveric-vericiguat-10-mgx98-tablets\/","title":{"rendered":"LuciVeric"},"content":{"rendered":"
\n
\n
<\/div>\n
\n
<\/div>\n<\/div>\n
\n
<\/div>\n<\/div>\n
<\/div>\n
\n
<\/div>\n<\/div>\n
\n
<\/div>\n<\/div>\n
\n
<\/div>\n<\/div>\n
\n
<\/div>\n<\/div>\n
<\/div>\n
\n
<\/div>\n<\/div>\n
\n
<\/div>\n<\/div>\n
<\/div>\n
\n
\n
<\/div>\n
<\/div>\n<\/div>\n
\n
<\/div>\n<\/div>\n<\/div>\n
\n
\n
<\/div>\n
<\/div>\n<\/div>\n
\n
<\/div>\n<\/div>\n<\/div>\n
<\/div>\n
\n
<\/div>\n<\/div>\n
<\/div>\n
\n
<\/div>\n<\/div>\n
\n
<\/div>\n<\/div>\n
<\/div>\n
\n
<\/div>\n<\/div>\n
\n
<\/div>\n<\/div>\n
p<\/span><\/span><\/span><\/div>\n
<\/div>\n
\u5fae\u8f6f\u96c5\u9ed1<\/span><\/span><\/span><\/div>\n
16<\/span><\/span><\/span><\/div>\n
<\/div>\n
\n
<\/div>\n<\/div>\n
\n
<\/div>\n<\/div>\n
\n
<\/div>\n<\/div>\n
<\/div>\n
\n
<\/div>\n<\/div>\n
\n
<\/div>\n<\/div>\n
<\/div>\n
\n
<\/div>\n<\/div>\n
\n
<\/div>\n<\/div>\n
\n
<\/div>\n<\/div>\n
<\/div>\n
\n
<\/div>\n<\/div>\n
<\/div>\n
\n
<\/div>\n<\/div>\n
\n
<\/div>\n<\/div>\n
\n
<\/div>\n<\/div>\n
\n
<\/div>\n<\/div>\n<\/div>\n
<\/div>\n<\/div>\n
\n
\n

HIGHLIGHTS OF PRESCRIBING INFORMATION<\/strong><\/span><\/p>\n

These highlights do not include all the information needed to use LuciVeric safely and effectively. See full prescribing information for LuciVeric.<\/span><\/p>\n

 <\/span><\/p>\n

INDICATIONS AND USAGE<\/strong><\/strong><\/span><\/p>\n

LuciVeric is a soluble guanylate cyclase (sGC) stimulator, indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%.<\/span><\/p>\n

 <\/span><\/p>\n

DOSAGE AND ADMINISTRATION<\/strong><\/strong><\/span><\/p>\n

\u00b7 The recommended starting dose of LuciVeric is 2.5 mg orally once daily with food.<\/span><\/p>\n

\u00b7 Double the dose of LuciVeric approximately every 2 weeks to reach the target maintenance dose of 10 mg once daily, as tolerated by the patient.<\/span><\/p>\n

\u00b7 Tablets may be crushed and mixed with water for patients who have difficulty swallowing.<\/span><\/p>\n

 <\/span><\/p>\n

DOSAGE FORMS AND STRENGTHS<\/strong><\/strong><\/span><\/p>\n

Tablets: 10 mg\u00d798 tablets<\/span><\/p>\n

 <\/span><\/p>\n

CONTRAINDICATIONS<\/strong><\/strong><\/span><\/p>\n

\u2022 Patients with concomitant use of other soluble guanylate cyclase (sGC) stimulators.<\/span><\/p>\n

\u2022 Pregnancy<\/span><\/p>\n

 <\/span><\/p>\n

WARNINGS AND PRECAUTIONS<\/strong><\/strong><\/span><\/p>\n

Based on data from animal reproduction studies, LuciVeric may cause fetal harm when administered to a pregnant woman. Advise females of reproductive potential of the potential risk to a fetus. Obtain a pregnancy test before the start of treatment. Advise females of reproductive potential to use effective contraception during treatment with LuciVeric and for at least one month after the final dose.<\/span><\/p>\n

 <\/span><\/p>\n

ADVERSE REACTIONS<\/strong><\/strong><\/span><\/p>\n

Most common adverse reactions reported in \u22655% are hypotension and anemia.<\/span><\/p>\n

 <\/span><\/p>\n

DRUG INTERACTIONS<\/strong><\/strong><\/span><\/p>\n

\u2022 PDE-5 Inhibitors: Concomitant use is not recommended.<\/span><\/p>\n

 <\/span><\/p>\n

USE IN SPECIFIC POPULATIONS<\/strong><\/strong><\/span><\/p>\n

\u2022 Lactation: Breastfeeding is not recommended.<\/span><\/p>\n

 <\/span><\/p>\n

Storage<\/strong><\/strong><\/span><\/p>\n

Store at 20\u00b0C to 25\u00b0C (68\u00b0F to 77\u00b0F), excursions permitted between 15\u00b0C and 30\u00b0C (59\u00b0F and 86\u00b0F) [see USP Controlled Room Temperature]. Protect from moisture. <\/span><\/p>\n

<\/p>\n<\/div>\n<\/div>\n

<\/p>\n","protected":false},"excerpt":{"rendered":"

LuciVeric is a soluble guanylate cyclase (sGC) stimulator, indicated to reduce the risk of cardiovascular death and heart failure (HF) hospitalization following a hospitalization for heart failure or need for outpatient IV diuretics, in adults with symptomatic chronic HF and ejection fraction less than 45%.<\/p>","protected":false},"featured_media":2157,"comment_status":"open","ping_status":"closed","template":"","meta":{"advanced_seo_description":"","jetpack_seo_html_title":"","jetpack_seo_noindex":false,"jetpack_seo_schema_type":""},"product_brand":[],"product_cat":[48],"product_tag":[],"class_list":["post-751","product","type-product","status-publish","has-post-thumbnail","product_cat-other-medicines","first","instock","shipping-taxable","purchasable","product-type-simple"],"jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/luciuspharmacy.com\/pt\/wp-json\/wp\/v2\/product\/751","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/luciuspharmacy.com\/pt\/wp-json\/wp\/v2\/product"}],"about":[{"href":"https:\/\/luciuspharmacy.com\/pt\/wp-json\/wp\/v2\/types\/product"}],"replies":[{"embeddable":true,"href":"https:\/\/luciuspharmacy.com\/pt\/wp-json\/wp\/v2\/comments?post=751"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/luciuspharmacy.com\/pt\/wp-json\/wp\/v2\/media\/2157"}],"wp:attachment":[{"href":"https:\/\/luciuspharmacy.com\/pt\/wp-json\/wp\/v2\/media?parent=751"}],"wp:term":[{"taxonomy":"product_brand","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/pt\/wp-json\/wp\/v2\/product_brand?post=751"},{"taxonomy":"product_cat","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/pt\/wp-json\/wp\/v2\/product_cat?post=751"},{"taxonomy":"product_tag","embeddable":true,"href":"https:\/\/luciuspharmacy.com\/pt\/wp-json\/wp\/v2\/product_tag?post=751"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}